Our Mission...
is to improve the quality of health service delivery and reduce the burden of disease and disability in the United States and elsewhere by carrying out broadly based research and education activities involving the translation of innovative medical research into practice

PUBLICATIONS

2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004

 

2009

de la Chapelle A, Palomaki GE, Hampel H: Identifying Lynch syndrome. Int J Cancer, 125:1492-1493, 2009.

Lambert-Messerlian G, Palomaki GE, Canick JA: Adjustment of serum markers in first trimester screening. J Med Screen, 16:102-103, 2009.

Lambert-Messerlian G, Palomaki GE, Neveux LM, Chien E, Friedman A, Rosene-Montella K, Hayes M, Canick JA: Early onset preeclampsia and second trimester serum markers. Prenat Diagn, 29:1109-1117, 2009.

Marcos J, Craig WY, Palomaki GE, Kloza EM, Haddow JE, Roberson M, Bradley LA, Shackleton CHL: Maternal urine and serum steroid measurements to identify steroid sulftase deficiency (STSD) in second trimester pregnancies. Prenat Diagn, 29:771-780, 2009.

Palomaki GE, Lee JE, Canick JA, McDowell GA, Donnenfeld AE; for the ACMG Laboratory Quality Assurance Committee: Technical standards and guidelines: Prenatal screening for Down syndrome that includes first-trimester biochemistry and/or ultrasound measurements. Genet Med, 11:669-681, 2009.

Palomaki GE, Bradley LA, Douglas MP, Kolor K, Dotson DW: Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med, 11:21-34, 2009.

Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN: EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med, 11:42-65, 2009.

Recommendations from the EGAPP Working Group: Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med, 11:35-41, 2009.

Recommendations from the EGAPP Working Group: Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet Med, 11:15-20, 2009.

Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, Dotson DW, Doublas MP, Berg AO, Chair, on behalf of the EGAPP Working Group: The evaluation of genomic applications in practice and prevention (EGAPP) initiative: methods of the EGAPP Working Group. Genet Med, 11:3-14, 2009.